文献速递胸部肿瘤

EGFR酪氨酸激酶抑制剂在非小细胞肺癌少见非20外显子插入EGFR突变中的治疗进展

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
PubMed 文献 · J Thorac Oncol · 2020-12-14

本文综述了EGFR-TKI在携带少见非20外显子插入EGFR突变的NSCLC患者中的最新临床前和临床数据,指出10%至20%的NSCLC患者携带对TKI敏感性各异的少见突变,且高达25%的病例存在复合突变;阿法替尼、达可替尼和奥希替尼因分子结构具有更广的抑制谱,但前瞻性数据匮乏、突变异质性强及复合突变使治疗决策复杂化,作者据此提出治疗策略建议并强调一线分子检测应纳入少见EGFR突变。

要点

  • 10%至20%的NSCLC患者携带少见EGFR突变,对TKI敏感性各异。
  • 阿法替尼、达可替尼和奥希替尼抑制谱较第一代TKI更广。
  • 高达25%的病例存在复合突变,增加治疗决策复杂性。

核心结论

  • 少见EGFR突变异质性强且前瞻性数据匮乏,治疗需个体化选择TKI。
  • 一线分子分析应纳入少见EGFR突变以优化患者结局。

研究设计与样本

  • 综述汇总不同TKI对主要少见EGFR突变(含复合突变、排除20外显子插入)的临床前和临床数据。

主要发现

  • 10%至20%的NSCLC患者携带对TKI敏感性各异的少见EGFR突变。
  • 阿法替尼、达可替尼和奥希替尼因分子结构具有更广的抑制谱。
  • 高达25%的病例存在复合突变。

临床怎么用

  • 根据精确基因型选择TKI以优化少见EGFR突变患者的结局。
  • 一线分子分析应纳入少见EGFR突变检测。

局限性

  • 少见EGFR突变的前瞻性临床数据匮乏。
  • 少见突变异质性强且复合突变常见,增加治疗决策难度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The first-line treatment of choice for patients with EGFR mutation-positive NSCLC is an EGFR tyrosine kinase inhibitor (TKI), of which five as follows are predominantly available in practice: gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib. Most prospective clinical trial data with these agents are limited to patients with the common activating and sensitizing EGFR mutations as follows: exon 19 deletions and exon 21 L858R point mutations. However, 10% to 20% of patients with NSCLC harbor uncommon EGFR mutations that have variable sensitivity to different EGFR TKIs. Owing to their molecular structures, afatinib, dacomitinib, and osimertinib have broader inhibitory profiles than the first-generation agents, gefitinib and erlotinib. Nevertheless, the paucity of prospective clinical data, the wide heterogeneity of uncommon mutations, and the existence of compound mutations in up to 25% of the cases complicate treatment decisions in this patient subgroup. Here, we collate the latest preclinical and clinical data regarding the activity of different TKIs against major uncommon EGFR mutations including compound mutations, but excluding exon 20 insertions which are generally insensitive to TKIs. On the basis of these data, we offer suggestions regarding treatment strategies for uncommon EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations in the first-line molecular analysis of all patients with adenocarcinoma of the lung, as this will help optimize patient outcomes according to their precise genotype.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Passaro A, Mok T, Peters S, et al. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2020. PMID: 33333327. doi:10.1016/j.jtho.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。